TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30316742

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (sham tDCS)
Number of subjects: 28
Study: 29630787

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice (1,100 ppm fluoride)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 1.5% arginine-containing dentifrice (Colgate Maximum Cavity Protection, 1,450 ppm fluoride)
Number of subjects: 35
Study: 27621414

Group type: EXPERIMENTAL
Intervention: Cups
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Teaspoon‐only label with milliliter and teaspoon tool
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Syringes (0.2‐ and 0.5‐mL increments)
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Overall dosing error
Number of subjects: 2110
Study: 25558545

Group type: EXPERIMENTAL
Intervention: Hyperbaric pressure at 607.95 kPa (6 atm abs)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Surface learning (101.325 kPa, 1 atm abs)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Psychological and biographical factors
Number of subjects: 139
Study: 22122880

Group type: EXPERIMENTAL
Intervention: Tapering of daytime benzodiazepines
Number of subjects: 30
Study: 20178935

Group type: EXPERIMENTAL
Intervention: A priori liking manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disliking a target
Number of subjects: 0
Study: 17275507

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 25

Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 25
Study: 15611002

Group type: EXPERIMENTAL
Intervention: Video-based awareness program
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 271
Study: 12435975

Group type: EXPERIMENTAL
Intervention: Side‐posture spinal adjusting (manipulation)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Side‐posture positioning
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 64
Study: 9932687

Group type: EXPERIMENTAL
Intervention: New ATLS course (1997)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Old ATLS course (1993)
Number of subjects: 32
Study: 7586343

Group type: COMPARATOR
Intervention: Systolic Blood Pressure (SBP) < 140 mm Hg
Number of subjects: 5362

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) >= 140 mm Hg
Number of subjects: 5362

Group type: COMPARATOR
Intervention: Diastolic Blood Pressure (DBP) < 70 mm Hg
Number of subjects: 5362

Group type: COMPARATOR
Intervention: Diastolic Blood Pressure (DBP) 70 to 79 mm Hg
Number of subjects: 5362

Group type: COMPARATOR
Intervention: Diastolic Blood Pressure (DBP) 80 to 89 mm Hg
Number of subjects: 5362

Group type: COMPARATOR
Intervention: Diastolic Blood Pressure (DBP) 90 to 99 mm Hg
Number of subjects: 5362

Group type: COMPARATOR
Intervention: Diastolic Blood Pressure (DBP) >= 100 mm Hg
Number of subjects: 5362

Group type: EXPERIMENTAL
Intervention: SBP >= 140 mm Hg
Number of subjects: 5362
Study: 2408233

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (3.8 micromol [200 micrograms] chromium)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 43682

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219

Group type: COMPARATOR
Intervention: 90% Alcohol (10-6 ml)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Diazepam and Lorazepam
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo, Alcohol, and Diazepam
Number of subjects: 219
Study: 31388104

Group type: EXPERIMENTAL
Intervention: MDD participants (N=106)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: MDD participants (N=58)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Healthy controls (N=36)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Healthy controls (N=58)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: MDD participants
Number of subjects: 164
Study: 30838448

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (no RIPC)
Number of subjects: 206
Study: 29024325

Group type: EXPERIMENTAL
Intervention: 1 mg/kg p-synephrine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 2 mg/kg p-synephrine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 3 mg/kg p-synephrine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 26749578

Group type: EXPERIMENTAL
Intervention: PATHS to PAX (integrated program of PAX GBG and PATHS)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: PAX Good Behavior Game (PAX GBG)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 350
Study: 24585500

Group type: EXPERIMENTAL
Intervention: Group mindfulness meditation for 6 weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Individual mindfulness meditation for 6 weeks
Number of subjects: 170
Study: 22349568

Group type: EXPERIMENTAL
Intervention: Laparoscopic partial nephrectomy (LPN) with warm ischemia
Number of subjects: 54
Study: 20809735

Group type: EXPERIMENTAL
Intervention: Biodegradable cages (70/30 poly(l‐lactide‐co‐d,l‐lactide) (PLDLA))
Number of subjects: 81

Group type: COMPARATOR
Intervention: Carbon fiber cages
Number of subjects: 81
Study: 18084799

Group type: EXPERIMENTAL
Intervention: Unifocal pacing (UP)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bifocal pacing (BP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Back-up pacing
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Overdrive pacing
Number of subjects: 19
Study: 15585598

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (Epi) during hyperinsulinemic euglycemic clamp studies
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (Epi)
Number of subjects: 34
Study: 12198053

Group type: EXPERIMENTAL
Intervention: Acoustic reflectometry
Number of subjects: 0
Study: 10996882

Group type: EXPERIMENTAL
Intervention: Standard treatment plus group therapy (TG+)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard treatment alone (TG-)
Number of subjects: 88
Study: 8629922

Group type: EXPERIMENTAL
Intervention: Bolus intrathecal injection of 50 micrograms baclofen
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 11
Study: 1309633

Group type: EXPERIMENTAL
Intervention: PI regimen (cisplatin 80 mg/m2 dl and ifosfamide 2 g/m2 d 1, 2, 3, q 3‐4 wks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: PV regimen (cisplatin 80 mg/m2 d 1 and vindesine 3 mg/m2 d 1, 8, 15, q 3‐4 wks)
Number of subjects: 83
Study: 6152804

Group type: EXPERIMENTAL
Intervention: 15 mg megestrol acetate and 5 mg estradiol valerate
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Microencapsulated megestrol compound
Number of subjects: 828

Group type: COMPARATOR
Intervention: Other three regimens (not specified)
Number of subjects: 828
Study: 30213739

Group type: EXPERIMENTAL
Intervention: Self-paced viewing of video tutorials
Number of subjects: 35

Group type: COMPARATOR
Intervention: Group viewing of video tutorials
Number of subjects: 35
Study: 30137497

Group type: EXPERIMENTAL
Intervention: The ABCDs of Pain Management video
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 128
Study: 27394385

Group type: EXPERIMENTAL
Intervention: HIT intervention (multi-component approach including web-based provider training, multimedia electronic screening, risk assessment scores, clinical decision support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25046844

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIPostC)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 21967563

Group type: EXPERIMENTAL
Intervention: Informed situation (external store with explicit information on gains, losses, and probabilities)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noninformed situation (age-adapted Iowa Gambling Task)
Number of subjects: 0
Study: 20691834

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (1 g/d)
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg/d)
Number of subjects: 1229

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1229
Study: 19026871

Group type: EXPERIMENTAL
Intervention: 1.8 mL of 1% diphenhydramine with 1:100,000 epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3.6 mL of 2% lidocaine with 1:100,000 epinephrine combined with 1% diphenhydramine with 1:100,000 epinephrine
Number of subjects: 0
Study: 15781499

Group type: COMPARATOR
Intervention: General Anesthesia (GA) with fentanyl (7-15 microg/kg) and morphine infusion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High Thoracic Epidural Anesthesia (HTEA) with fentanyl (5-7 microg/kg) and epidural infusion of ropivacaine 0.2% and fentanyl 2 microg/mL until postoperative Day 3
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High Thoracic Epidural Anesthesia (HTEA)
Number of subjects: 120
Study: 12519833

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/d orally)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 11508548

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (500 microg/d)
Number of subjects: 27
Study: 8645639

Group type: EXPERIMENTAL
Intervention: Routine midtrimester ultrasound examination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective obstetric ultrasonography
Number of subjects: 0
Study: 1346410

Group type: EXPERIMENTAL
Intervention: Cyclosporin (5 mg/kg per day for 12 weeks)
Number of subjects: 33
Study: 31983187

Group type: EXPERIMENTAL
Intervention: B-CAM-M (Malay version of Breast Cancer Awareness Measure)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: B-CAM-M
Number of subjects: 251
Study: 31167001

Group type: EXPERIMENTAL
Intervention: Thermal stimulation at different temperatures (including 44°C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thermal stimulation at 44°C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Same thermal stimulation
Number of subjects: 0
Study: 29960287

Group type: EXPERIMENTAL
Intervention: Qinbei Qingfei Yiqi (QBQFYQ) granules plus usual treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 80
Study: 26457385

Group type: EXPERIMENTAL
Intervention: Multifaceted behavioral group intervention
Number of subjects: 178

Group type: COMPARATOR
Intervention: Supportive group intervention
Number of subjects: 178
Study: 23756075

Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (C‐A‐T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Special Operations Forces Tactical Tourniquet Wide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other tourniquet types
Number of subjects: 0
Study: 22259899

Group type: EXPERIMENTAL
Intervention: General anaesthesia combined with nerve stimulator guided bilateral paravertebral block
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anaesthesia combined with normal saline nerve stimulator guided bilateral paravertebral block
Number of subjects: 60
Study: 19303966

Group type: EXPERIMENTAL
Intervention: Low-dose supplemental vitamins E plus C
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Medium-dose supplemental vitamins E plus C
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High-dose supplemental vitamins E plus C
Number of subjects: 4

Group type: COMPARATOR
Intervention: No vitamins
Number of subjects: 4
Study: 17535222

Group type: EXPERIMENTAL
Intervention: Nursing programme 'Coping with Itch' (mean of 2.9 visits)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care from a dermatologist (control group)
Number of subjects: 65
Study: 15156934

Group type: EXPERIMENTAL
Intervention: Cranberry supplement (400 mg, 3 times a day for 4 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11493247

Group type: EXPERIMENTAL
Intervention: Bicarbonate group (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline group (n = 20)
Number of subjects: 40
Study: 9929676

Group type: EXPERIMENTAL
Intervention: Olfactory problem
Number of subjects: 80000

Group type: EXPERIMENTAL
Intervention: Gustatory problem
Number of subjects: 80000

Group type: EXPERIMENTAL
Intervention: Chemosensory problem (combined smell and taste)
Number of subjects: 80000

Group type: EXPERIMENTAL
Intervention: Age group 65 years or greater with chemosensory problem
Number of subjects: 80000

Group type: EXPERIMENTAL
Intervention: Health-related characteristics
Number of subjects: 80000
Study: 8057219

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate formula (CHF)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cow-milk formula (CMF)
Number of subjects: 130
Study: 3377928

Group type: EXPERIMENTAL
Intervention: Midazolam 5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 8
Study: 31916919

Group type: EXPERIMENTAL
Intervention: KORSA workshops (4-week intervention)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 124
Study: 30554216

Group type: EXPERIMENTAL
Intervention: Solid diet (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Liquid diet (n = 50)
Number of subjects: 100
Study: 27817037

Group type: EXPERIMENTAL
Intervention: Underweight (<18.5 kg/m2)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Normal weight (19‐23.9 kg/m2)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Overweight (24‐27.9 kg/m2)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Obese (≥28 kg/m2)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Total recombinant follicle‐stimulating hormone (rFSH) dose
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Clinical pregnancy rate per transfer
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Biochemical pregnancy rate
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Ongoing pregnancy rate
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Miscarriage rate
Number of subjects: 800
Study: 25951232

Group type: EXPERIMENTAL
Intervention: Erlotinib plus nab-paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 0
Study: 24053627

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid administered 24 hours after endoscopic procedure for 14 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 2
Study: 20963602

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided reduction
Number of subjects: 68

Group type: COMPARATOR
Intervention: Simple closed reduction
Number of subjects: 68
Study: 19820872

Group type: EXPERIMENTAL
Intervention: Vaginal estriol therapy for 14 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no estriol therapy)
Number of subjects: 27
Study: 17364516

Group type: EXPERIMENTAL
Intervention: Computerized working memory training for five weeks
Number of subjects: 18
Study: 14751328

Group type: EXPERIMENTAL
Intervention: Teaching intervention with photo book (Group A, n=49)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Teaching intervention only (Group B, n=51)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 100
Study: 11887979

Group type: EXPERIMENTAL
Intervention: Predictions made by clinicians (internist, surgeon, general practitioner)
Number of subjects: 402
Study: 9227927

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b combined with cytarabine (20 mg per square meter per day for 10 days, plus hydroxyurea 50 mg per kilogram per day)
Number of subjects: 721

Group type: COMPARATOR
Intervention: Interferon alfa-2b alone (plus hydroxyurea 50 mg per kilogram per day)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b combined with cytarabine
Number of subjects: 721

Group type: COMPARATOR
Intervention: Interferon alone
Number of subjects: 721
Study: 7954535

Group type: EXPERIMENTAL
Intervention: Furosemide, 25 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Torasemide, 10 mg/day
Number of subjects: 12
Study: 3664553

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 179

Group type: COMPARATOR
Intervention: Aspirin with codeine
Number of subjects: 179
Study: 31957269

Group type: COMPARATOR
Intervention: Mindfulness relaxation (MR)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Relaxing music (RM)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Standard care (SC)
Number of subjects: 474
Study: 30908421

Group type: EXPERIMENTAL
Intervention: Bonfils fiberscope
Number of subjects: 15

Group type: COMPARATOR
Intervention: SensaScope fiberscope
Number of subjects: 15
Study: 28058750

Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg
Number of subjects: 222

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg after 52 weeks
Number of subjects: 222

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg after 52 weeks
Number of subjects: 222
Study: 26232505

Group type: EXPERIMENTAL
Intervention: Galactooligosaccharide (1.7 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 20
Study: 23394340

Group type: EXPERIMENTAL
Intervention: Phenytoin for 7 days after tumor resection (prophylaxis group)
Number of subjects: 123

Group type: COMPARATOR
Intervention: No seizure prophylaxis (observation group)
Number of subjects: 123
Study: 21360125

Group type: EXPERIMENTAL
Intervention: Autologous conditioned serum (ACS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 19159475

Group type: EXPERIMENTAL
Intervention: Injectable heroin maintenance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 0
Study: 17876014

Group type: EXPERIMENTAL
Intervention: Erlotinib (Erl) 150 mg daily combined with Bevacizumab (Bev) 10 mg/kg every 2 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bevacizumab (Bev) 10 mg/kg every 2 weeks
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Erlotinib (Erl) combined with Bevacizumab (Bev)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bevacizumab (Bev) alone
Number of subjects: 104
Study: 16420077

Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg/day initiated, flexibly dosed to a maximum of 16 mg/day)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 266
Study: 12447511

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (ETI)
Number of subjects: 49
Study: 9593991

Group type: EXPERIMENTAL
Intervention: Landmark information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Landmark and geometric information
Number of subjects: 0
Study: 10155183

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodiafiltration
Number of subjects: 100
Study: 2146038

Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator (Alteplase or Duteplase)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (Anistreplase)
Number of subjects: 18
Study: 344156

Group type: EXPERIMENTAL
Intervention: Bran (high-fibre diet)
Number of subjects: 22
Study: 31789445

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study: 29893592

Group type: EXPERIMENTAL
Intervention: D-aspartic acid (DAA) 3 g/day for 2 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo 3 g/day for 2 weeks
Number of subjects: 16
Study: 28328065

Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS+50%FERM
Number of subjects: 432

Group type: COMPARATOR
Intervention: scGOS/lcFOS
Number of subjects: 432

Group type: COMPARATOR
Intervention: 50%FERM
Number of subjects: 432
Study: 25981371

Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 0
Study: 25008012

Group type: EXPERIMENTAL
Intervention: DASH-like diet high in protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DASH-like diet high in unsaturated fats
Number of subjects: 0

Group type: COMPARATOR
Intervention: DASH-like diet high in carbohydrates
Number of subjects: 0
Study: 21478659

Group type: EXPERIMENTAL
Intervention: Accelerated protocol (n=13)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Slow protocol (n=16)
Number of subjects: 29
Study: 18992951

Group type: EXPERIMENTAL
Intervention: PRS Type 1 (single exponential)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: PRS Type 2 (non-exponential)
Number of subjects: 270
Study: 16520409

Group type: EXPERIMENTAL
Intervention: Aldosterone (500 microg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Aldosterone with L‐NMMA
Number of subjects: 13

Group type: COMPARATOR
Intervention: L‐NMMA alone
Number of subjects: 13
Study: 15531664

Group type: EXPERIMENTAL
Intervention: Diet containing 3 g beta-glucan/d from barley
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Diet containing 6 g beta-glucan/d from barley
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control diet with no beta-glucan
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Whole grains incorporated into the diets
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 25
Study: 11050610

Group type: EXPERIMENTAL
Intervention: Medical care
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epidural steroid injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Self-care advice (minimal intervention control group)
Number of subjects: 20
Study: 9282055

Group type: EXPERIMENTAL
Intervention: K Care
Number of subjects: 20
Study: 8442804

Group type: EXPERIMENTAL
Intervention: Immediate cesarean section
Number of subjects: 38

Group type: COMPARATOR
Intervention: Observed labor
Number of subjects: 38
Study: 3107442

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (0.1 mg X kg‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg X kg‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6